Biohaven Ltd. (BHVN) stock
BHVNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 1/30
$12.90−0.34 (-2.57%)
Close on Nov 18, 2026Market cap $1.95BP/E –Yield –
Biohaven r&d expenses
Research and development expenses are spending on new products and technology.
Biohaven's R&D Expenses for the twelve months ending Sep 30, 2026 was $428.44M, down 37.0% year over year. For fiscal 2025 it was $635.07M, down 20.2% from the year before. The highest annual figure on record is $795.87M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $635.07M | -20.2% |
| FY2024 | Dec 31, 2024 | $795.87M | +113.2% |
| FY2023 | Dec 31, 2023 | $373.28M | -14.6% |
| FY2022 | Dec 31, 2022 | $437.07M | +140.8% |
| FY2021 | Dec 31, 2021 | $181.49M | +84.3% |
| FY2020 | Dec 31, 2020 | $98.46M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $101.85M | -27.9% |
| Q2 FY2026 | Jun 30, 2026 | $100.81M | -45.3% |
| Q1 FY2026 | Mar 31, 2026 | $103.83M | -44.7% |
| Q4 FY2025 | Dec 31, 2025 | $121.95M | -27.2% |
| Q3 FY2025 | Sep 30, 2025 | $141.17M | -10.4% |
| Q2 FY2025 | Jun 30, 2025 | $184.37M | -41.4% |
| Q1 FY2025 | Mar 31, 2025 | $187.58M | +20.3% |
| Q4 FY2024 | Dec 31, 2024 | $167.47M | +24.2% |
| Q3 FY2024 | Sep 30, 2024 | $157.61M | +65.0% |
| Q2 FY2024 | Jun 30, 2024 | $314.82M | +296.0% |
| Q1 FY2024 | Mar 31, 2024 | $155.97M | +145.8% |
| Q4 FY2023 | Dec 31, 2023 | $134.81M | -1.6% |
| Q3 FY2023 | Sep 30, 2023 | $95.52M | +80.7% |
| Q2 FY2023 | Jun 30, 2023 | $79.49M | -55.1% |
| Q1 FY2023 | Mar 31, 2023 | $63.46M | -9.5% |
| Q4 FY2022 | Dec 31, 2022 | $137.04M | +227.7% |
| Q3 FY2022 | Sep 30, 2022 | $52.85M | +12.5% |
| Q2 FY2022 | Jun 30, 2022 | $177.09M | – |
| Q1 FY2022 | Mar 31, 2022 | $70.10M | – |
| Q4 FY2021 | Dec 31, 2021 | $41.82M | – |
| Q3 FY2021 | Sep 30, 2021 | $46.97M | – |
See a number that looks wrong?